JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 24 No. 1 39-44
© 1983 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peters, A. M.
Right arrow Articles by Lavender, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peters, A. M.
Right arrow Articles by Lavender, J. P.

Imaging of Inflammation with Indium-111 Tropolonate Labeled Leukocytes

A. Michael Peters, Sethna H. Saverymuttu, Helen J. Reavy, Heather J. Danpure, Safiye Osman and J. Peter Lavender

Hammersmith Hospital, London W12 OHS UK

Correspondence: For reprints contact: Dr. A. M. Peters, Dept. of Diagnostic Radiology, Hammersmith Hosp., Du Cane Raod, London W12 OHS UK.

ABSTRACT

Indium-111 tropolonate has recently been introduced as a new cell-labeling agent. It has the interesting property of labeling cells in plasma with high efficiency, and may therefore promote an improvement in viability of labeled cells. This paper describes our initial experience with In-111 tropolonate as a leukocyte label for abscess imaging. Pure populations of separated granulocytes, as well as crude leukocyte preparations, have been labeled. Of 101 studies performed, 51 were positive (no false positives) and 50 negatives, of which only two were false negatives. Localization in sites of inflammation was prominent and rapid. Of 36 positive studies, 27 were already positive at 40 min following injection and an additional nine at 3 hr. Of the other 15 positive studies, 11 were scanned for the first time at 3 hr, when they were positive. Granulocytes labeled with this agent in plasma showed minimal sequestration in lungs and liver, interpreted as indicating improved viability in comparison with cells displaying prolonged lung sequestration.




This article has been cited by other articles:


Home page
JNMHome page
M. Tulchinsky and A. M. Peters
Leukocyte Receptor-Binding Radiopharmaceuticals for Infection and Inflammation Scintigraphy
J. Nucl. Med., May 1, 2005; 46(5): 718 - 721.
[Full Text] [PDF]


Home page
JNMHome page
S. Gratz, H. J.J.M. Rennen, O. C. Boerman, W. J.G. Oyen, P. Burma, and F. H.M. Corstens
99mTc-Interleukin-8 for Imaging Acute Osteomyelitis
J. Nucl. Med., August 1, 2001; 42(8): 1257 - 1264.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
J. M. Murphy, K. K. Balan, A. Toms, B. Gomez-Anson, and M. Lockwood
Radiolabeled Leucocyte Imaging in Diffuse Granulomatous Involvement of the Meninges in Wegener's Granulomatosis: Scintigraphic Findings and Their Role in Monitoring Treatment Response to Specific Immunotherapy (Humanized Monoclonal Antilymphocyte Antibodies)
AJNR Am. J. Neuroradiol., August 1, 2000; 21(8): 1460 - 1465.
[Abstract] [Full Text]


Home page
Rheumatology (Oxford)Home page
A. M. Peters
Nuclear medicine in vasculitis
Rheumatology, May 1, 2000; 39(5): 463 - 470.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1983 by the Society of Nuclear Medicine.